TXG: financial statements from SEC — TradeAlmanac

TXG

10x Genomics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	643m	611m
Cost of revenue	199m	196m
Gross profit	444m	414m
Selling, general and administrative	316m	344m
Operating expenses	505m	609m
Operating income	−61m	−195m
Pre-tax income	−40m	−178m
Income tax	4m	5m
Net income	−44m	−183m
Earnings per share	−0.35	−1.52
Earnings per share, diluted	−0.35	−1.52
Weighted average shares	125m	120m
Weighted average shares, diluted	125m	120m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	490m	474m	433m	398m	377m	344m	398m	380m
Receivables	39m	47m	44m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	136m	7m
Depreciation and amortisation	36m	36m
Share-based compensation	109m	141m
Capital expenditure	6m	12m
Investing cash flow	−13m	−33m
Financing cash flow	7m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)